Product Information
METRONIDAZOLE VAGINAL 0.75% GL is a generic product labeled by Solaris Pharma Corporation, priced at $0.1406 per GM under NDC 73473030370. Its NADAC has been published 251 times since Dec 15, 2021.
FDA first approved this application on Oct 14, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
7.5 mg/g
Manufacturer
Solaris Pharma CorporationNDC
73473030370
Classification
Generic
Dosage Form
GEL
Route
VAGINAL
Effective Date
9/23/2026
Active Ingredients
METRONIDAZOLEApproval Type
Generic (ANDA)
FDA Application
ANDA213648FDA Approved
10/14/2021
TE Code
AB
On Market Since
1/8/2026
Pharmacological Classes
Price Statistics
The NADAC for METRONIDAZOLE VAGINAL 0.75% GL has been published 251 times since Dec 15, 2021, and over the history we have for it it has declined 83.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1406 per GM |
|---|---|
| All-time high | $0.8341 (Dec 15, 2021) |
| All-time low | $0.1405 (Jul 22, 2026) |
| 52-week high | $0.1847 |
| 52-week low | $0.1405 |
| Median price | $0.3014 |
| Average price | $0.3525 |
| Largest weekly change | -40.7% (Nov 20, 2024) |
| Weeks tracked | 251 |
| Tracking since | Dec 15, 2021 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Solaris Pharma Corporation manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Metronidazole market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nitroimidazole Antimicrobial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of METRONIDAZOLE VAGINAL 0.75% GL?
The current National Average Drug Acquisition Cost (NADAC) for METRONIDAZOLE VAGINAL 0.75% GL, manufactured by Solaris Pharma Corporation, is $0.1406 per GM (NDC 73473030370), effective Sep 30, 2026.
How has the price of METRONIDAZOLE VAGINAL 0.75% GL changed over time?
Over the history we have for it, the NADAC for METRONIDAZOLE VAGINAL 0.75% GL has declined 83.1%. It has been tracked across 251 weekly CMS publications since Dec 15, 2021.
What are the highest and lowest recorded NADAC prices for METRONIDAZOLE VAGINAL 0.75% GL?
Since Dec 15, 2021, the NADAC for METRONIDAZOLE VAGINAL 0.75% GL has ranged from a low of $0.1405 (Jul 22, 2026) to a high of $0.8341 (Dec 15, 2021), with a median of $0.3014 per GM.
Are there cheaper alternatives to METRONIDAZOLE VAGINAL 0.75% GL?
5 manufacturers publish a NADAC-priced product with the same active ingredient and strength as METRONIDAZOLE VAGINAL 0.75% GL in a comparable dosage form, but none are currently priced below it.
Who manufactures METRONIDAZOLE VAGINAL 0.75% GL?
METRONIDAZOLE VAGINAL 0.75% GL (NDC 73473030370) is labeled by Solaris Pharma Corporation, and CMS classifies it as a generic product.